Progyny

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Progyny and other ETFs, options, and stocks.

About PGNY

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. 

CEO
Peter Anevski
CEOPeter Anevski
Employees
856
Employees856
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2008
Founded2008
Employees
856
Employees856

PGNY Key Statistics

Market cap
2.00B
Market cap2.00B
Price-Earnings ratio
33.19
Price-Earnings ratio33.19
Dividend yield
Dividend yield
Average volume
1.58M
Average volume1.58M
High today
$25.91
High today$25.91
Low today
$25.28
Low today$25.28
Open price
$25.68
Open price$25.68
Volume
1.25M
Volume1.25M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$16.10
52 Week low$16.10

Stock Snapshot

Progyny(PGNY) stock is priced at $25.56, giving the company a market capitalization of 2B. It carries a P/E multiple of 33.19.

During the trading session on 2026-05-31, Progyny(PGNY) shares reached a daily high of $25.91 and a low of $25.28. At a current price of $25.56, the stock is +1.1% higher than the low and still -1.3% under the high.

Trading activity shows a volume of 1.25M, compared to an average daily volume of 1.58M.

The stock's 52-week range extends from a low of $16.10 to a high of $28.75.

The stock's 52-week range extends from a low of $16.10 to a high of $28.75.

PGNY News

Nasdaq 1h
A Progyny Insider Sold 5,500 Shares for $137,000

Key Points Kevin Gordon sold 5,500 shares on May 27, 2026, at a weighted average price of around $24.99 per share, for a total transaction value of ~$137,000....

A Progyny Insider Sold 5,500 Shares for $137,000
TipRanks 2d
Progyny Insider Makes a Notable Move With Fresh Stock Sale

New insider activity at Progyny ( (PGNY) ) has taken place on May 29, 2026. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst rat...

TipRanks 4d
Progyny Shareholders Approve Governance Changes at 2026 Meeting

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

More PGNY News

Simply Wall St 4d
Progyny Buyback Raises Questions On Capital Returns And Growth Plans

Progyny (NasdaqGS:PGNY) announced a US$200 million share repurchase program approved by its Board. The authorization allows the company to buy back its common...

Progyny Buyback Raises Questions On Capital Returns And Growth Plans
TipRanks 5d
Progyny announces $200M share repurchase program

Progyny (PGNY) announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program w...

Investing.com 5d
Progyny authorizes $200 million share buyback program - Investing.com

...

Progyny authorizes $200 million share buyback program - Investing.com
Nasdaq 5d
Progyny Authorized Up To $200 Mln Buyback

(RTTNews) - Progyny, Inc. (PGNY), a women's health and family building solutions company, Tuesday announced that it has been authorized to repurchase up to $200...

Progyny Authorized Up To $200 Mln Buyback

People also own

Based on the portfolios of people who own PGNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.